Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.35 |
| ▸ | RAF1 | P04049 | 3/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049963 | 0.82 | MAPK14 (0.43) | MAPK14MAPTAAK1MAPK13MAPK11 | |
| SCHEMBL7813599 | 0.82 | MAPK13 (0.48) | MAPK14AAK1MAPK13RAF1 | |
| SCHEMBL7811987 | 0.79 | MAPK14 (0.58) | MAPK14MAPTAAK1MAPK13MAPK11 | |
| SCHEMBL3628470 | 0.77 | MAPK14 (0.58) | MAPK14MAPTAAK1MAPK13MAPK11 | |
| SCHEMBL27842253 | 0.77 | MAPK14 (0.54) | MAPK14AAK1MAPK13MAPK11RAF1 | |
| SCHEMBL7810441 | 0.77 | MAPK13 (0.54) | MAPK14AAK1MAPK13MAPK11RAF1 | |
| SCHEMBL7131276 | 0.77 | MAPK14 (0.44) | MAPK14MAPK13MAPK11GRNSORT1 | |
| SCHEMBL5307032 | 0.76 | GRN (0.36) | MAPK14MAPTMAPK13MAPK11KDM4E | |
| SCHEMBL7811988 | 0.75 | MAPK14 (0.49) | MAPK14MAPTAAK1MAPK13MAPK11 | |
| SCHEMBL3629677 | 0.72 | AAK1 (0.40) | MAPK14MAPTAAK1MAPK13MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4403482-B2 | — | — | 2010-01-27 | — | — | JP | claimed |
| EP-1041982-A4 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-14 | — | — | EP | claimed |
| JP-2001526223-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | claimed |
| EP-1041982-A4 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1047418-A4 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER AG (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-1047418-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-11-02 | — | — | EP | disclosed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032106-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |